A Clinical Study of Intravenous Immunoglobulin
Phase 3
Completed
- Conditions
- Immunologic Deficiency Syndromes
- Interventions
- Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- FFF Enterprises
- Target Recruit Count
- 57
- Registration Number
- NCT00468273
- Locations
- 🇺🇸
Mattel Children's Hospital of UCLA, Los Angeles, California, United States
🇺🇸1st Allergy and Clinical Research Center, Centennial, Colorado, United States
🇺🇸Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath